A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. @g0ingmad explains https://t.co/XSDJpoFUJs https://t.co/C1YpENKqgF ...